Lupin, China's SUP ink pact for COPD drug Tiotropium DPI
Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market.
Under the partnership that will enable Lupin to expand footprint in China, SUP will obtain regulatory approvals for selling Tiotropium DPI in China. Lupin will be the marketing authorisation holder and responsible for manufacturing of the product.
Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. Their partnership comes in backdrop of increasing prevalence of respiratory conditions, Lupin said in a release on Monday.
'This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector,' Lupin's President of Corporate Development Fabrice Egros said.
SUP president Wang Li said 'by bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.'
Lupin shares closed with a gain of less than 1% on the BSE at ₹2,010.55 each on Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
How America's new plan to cut China's supply chain for Apple, Google, Samsung and other technology companies has worried Vietnam
The United States reportedly has another plan to cut China's hardware and components supply chain of Apple, Google, Samsung, Meta and other technology companies. According to a report in Reuters, America is urging Vietnam to reduce Chinese technology in devices assembled in the country and exported to America. Vietnam, a hub for tech giants like Apple and Samsung, relies heavily on Chinese components, with Meta and Google also producing goods like VR headsets and smartphones there. Vietnam has held meetings with local businesses to increase the use of Vietnamese parts, with firms expressing willingness but noting the need for time and technology, one source told Reuters. Trump Tariffs: 46% tariff threat and ... The Trump administration has threatened 46% tariffs, which could disrupt Vietnam's export-driven economy. One source said that Vietnam was asked to "reduce its dependency on Chinese high-tech" to restructure supply chains and lessen US reliance on Chinese components. Another source highlighted the US goal of accelerating decoupling from Chinese tech while boosting Vietnam's industrial capacity, citing VR devices as an example. With a US-imposed tariff deadline of July 8 looming, the scope and timing of a potential deal reportedly remain uncertain. Sources emphasized that reducing Chinese high-tech content in exports is a US priority. Last year, China exported $44 billion in tech goods to Vietnam, 30% of its total exports there, while Vietnam shipped $33 billion in tech goods to the US, per Vietnam's customs data. The US also wants Vietnam to address Chinese goods mislabeled as "Made in Vietnam" to evade higher duties. Vietnam's trade ministry noted progress in recent Washington talks but said key issues remain unresolved. What is Vietnam's big worry Vietnam's Communist Party chief, To Lam, may meet President Trump in late June, though no date is confirmed, sources told Reuters. Local companies have shown willingness to adapt but warned that rapid changes could "destroy business," one source said. Industry experts note that Vietnam's supply chain lags China's by 15–20 years but is progressing in sectors like electronics. Abrupt shifts could strain Vietnam's ties with China, a key investor and also lead to security concerns.
New Indian Express
an hour ago
- New Indian Express
Rare earth magnet: Govt in talks at diplomatic, commercial levels
The government is engaged in both diplomatic and commercial discussions with China on supply restrictions on rare earth material, according to government sources. While the ministry of external affairs (MEA) and Ministry of commerce are in talks with their counterparts in China, the government is also facilitating the auto industry's talks with the Chinese suppliers, said a commerce ministry official. 'These are export controls, which China has invoked for the whole world. They have brought a regime where perhaps licenses will be required. So, we are facilitating our importers and our automobile makers in whatever way possible,' said the official, adding that these diplomatic and commercial communications should give a positive outcome. Though, he refused to give a timeline for finding a solution to the problem. The Indian automotive sector, particularly the electric vehicle (EV) segment, is grappling with a supply-chain disruption due to China's stringent export restrictions on rare earth magnets. These low-cost yet critical components are indispensable for modern vehicles, and their scarcity threatens to impact production, new model launches, and the industry's ambitious growth trajectory.
Mint
an hour ago
- Mint
Biocon shares in focus after board opens up QIP fundraising on 16 June, sets floor price at ₹340.20/share
Biocon shares will be in focus of stock market investors after the company's board of directors announce the opening of the QIP (Qualified Institutional Placement) fundraising on 16 June 2025, according to an exchange filing. 'The Fund Raising Committee has at its meeting held today, i.e. Monday, June 16, 2025, authorizing the opening of the issue,' said Biocon in the BSE filing. The pharma company also approved the floor price of the QIP issue to be at ₹ 340.20 per equity share. Biocon disclosed that the company has the ability to discount the offer further to not more than 5 per cent on the floor price of the QIP issue. 'The company may, at its discretion, offer a discount of not more than 5% on the floor price for the issue,' said Biocon in the exchange filing. The firm will decide the issue price after consultation with the book-running lead managers appointed in relation to the case. Biocon shares closed 0.52 per cent higher at ₹ 357.30 after Monday's stock market session, compared to ₹ 355.45 at the previous stock market close. The company announced the outcome of its board meeting after the market operating hours on 16 June 2025. Shares of the pharmaceutical company have given investors more than 637.35 per cent since its listing in the Indian stock market in 2004. However, the shares lost 6.37 per cent in the last five years. In the last one-year period, the stock has gained 8.71 per cent, and is trading 4.31 per cent higher in the last five stock market sessions. Biocon shares hit their 52-week high level at ₹ 404.60 on 21 January 2025, and the 52-week low level was at ₹ 290.80 on 3 March 2025, according to data collected from the BSE website. The pharma company's market capitalisation (M-Cap) was at ₹ 42,897.44 crore as of the stock market close on Monday, 16 June 2025.
